Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC
Thomas E. Stinchcombe, Robert C. Doebele, Xiaofei Wang, David E. Gerber, Leora Horn, D. Ross Camidge
Topics & Concepts
MedicineInternal medicineClinical endpointALK inhibitorOncologyAdverse effectClinical trialConfidence intervalProgressive diseasePhases of clinical researchProgression-free survivalGastroenterologyAnaplastic lymphoma kinaseDiseaseChemotherapyLung cancerMalignant pleural effusionLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment